BioCentury | Jun 14, 2018
Translation in Brief

There’s more to MIF

...a 2008 Nature study from Yale University suggested MIF and its interaction with another receptor, CD74 molecule major histocompatibility complex class II invariant chain...
...acute kidney injury after cardiac surgery.” Science Translational Medicine (2018) Jennie Walters, Staff Writer RWTH Aachen University Yale University CD74 molecule major histocompatibility complex class II invariant chain D-dopachrome...
BioCentury | Jun 5, 2018
Distillery Therapeutics

Renal

...promote cellular MIF release in animal models of AKI. TARGET/MARKER/PATHWAY: Macrophage migration inhibitory factor (MIF); CD74 molecule major histocompatibility complex class II invariant chain...
...Peter Boor, RWTH Aachen University, Aachen, Germany email: pboor@ukaachen.de Jennie Walters Ludwig Maximilians University of Munich RWTH Aachen University CD74 molecule major histocompatibility complex class II invariant chain Macrophage...
BioCentury | Oct 3, 2017
Distillery Therapeutics

Autoimmune disease

...ImmunoTherapeutics has RTL1000 in Phase I testing to treat both RRMS and progressive MS. TARGET/MARKER/PATHWAY: CD74 molecule major histocompatibility complex class II invariant chain...
...VA Portland Health Care System, Portland, Ore. email: vandenba@ohsu.edu Hongjiang Li Artielle ImmunoTherapeutics Inc. VA Portland Health Care System CD74 molecule major histocompatibility complex class II invariant chain D-dopachrome...
BioCentury | Aug 11, 2017
Company News

Sutro, Celgene revamping immuno-oncology deal

...additional collaborations or accessing the public financial market. STRO-001 is an ADC that targets the CD74 molecule major histocompatibility complex class II invariant chain...
...South San Francisco, Calif. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer Chris Lieu STRO-001 STRO-002 Celgene Corp. Sutro Biopharma Inc. CD74 molecule major histocompatibility complex class II invariant chain Folate...
BioCentury | Aug 10, 2017
Company News

Sutro, Celgene revamping immuno-oncology deal

...additional collaborations or accessing the public financial market. STRO-001 is an ADC that targets the CD74 molecule major histocompatibility complex class II invariant chain...
...update on the Merck deal (see BioCentury Extra, Sept. 17, 2014) . Chris Lieu STRO-001 STRO-002 Celgene Corp. Sutro Biopharma Inc. CD74 molecule major histocompatibility complex class II invariant chain Folate...
BioCentury | Sep 22, 2014
Company News

Seattle Genetics, Genmab deal

...companies partnered to use the ADC technology with Genmab's cancer candidate HuMax-CD74-ADC, an ADC against CD74 molecule major histocompatibility complex class II invariant chain...
BioCentury | Apr 25, 2011
Company News

Genmab, Seattle Genetics deal

...its antibody-drug conjugate (ADC) technology with Genmab's preclinical cancer candidate HuMax-CD74-ADC , an ADC against CD74 molecule major histocompatibility complex class II invariant chain...
BioCentury | Dec 13, 2010
Clinical News

Milatuzumab: Phase I/II data

...Immunomedics Inc. (NASDAQ:IMMU), Morris Plains, N.J. Product: Milatuzumab ( IMMU-115 ) Business: Cancer Molecular target: CD74 molecule major histocompatibility complex class II invariant chain...
BioCentury | Aug 2, 2010
Emerging Company Profile

Carolus: Targeting cytokines

...being one of the first cytokines discovered in 1962, because the only known receptor was CD74 molecule major histocompatibility complex class II invariant chain...
BioCentury | Jun 21, 2010
Clinical News

Milatuzumab-doxorubicin conjugate: Phase I/II started

...is identified. Immunomedics Inc. (NASDAQ:IMMU), Morris Plains, N.J. Product: Milatuzumab-doxorubicin conjugate Business: Cancer Molecular target: CD74 molecule major histocompatibility complex class II invariant chain...
Items per page:
1 - 10 of 11